This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. For more details about cookies and how to manage them see our Privacy Policy.

Bio-germ ranks No. 1 in the campaign of EQA/PT by NCCL on SARS-CoV-2 Omicron variant!

Since November 2021, the highly-infectious SARS-CoV-2 Omicron variant has spread rapidly and widely around the world, and become the concerned dominant variant in the WHO list.

Apr 07,2022

To figure out the effect of Omicron variant on existing PCR detection and to improve their detection quality, the China National Center for Clinical Laboratories specially carried out the national campaign of external quality assessment (EQA) / proficiency testing (PT) on SARS-CoV-2 Omicron variant.

China National Center for Clinical Laboratories is in charge of quality assessment and management commissioned by the administrative department of National Health and Family Planning Commission. One of the main functions of National Center for Clinical Laboratories is to provide the external quality assessment service.


The campaign was participated by 7668 laboratories from 31 provinces(municipalities and autonomous regions) in China, including CDCs, secondary/tertiary public medical institutions (general hospitals, specialized medical institutions, maternity and child care institutions), independent medical laboratories, and international travel healthcare centers under the customs, etc. 

(*Due to logistics control during the epidemic period, EQA samples couldn't be mailed 60 laboratories, and 7,608 laboratories actually participated in the campaign.)


Among them, 1605 laboratories used Bio-germ's nucleic acid detection reagents, accounting for more than 21.2% . Bio-germ ranks No.1 in the campaign of EQA/PT by NCCL on SARS-CoV-2 Omicron variant !

Bio-germ Medical’s wholly-owned subsidiary Bojian Medical Laboratory, participated and pass the assessment with full marks!

Bio-germ's nucleic acid detection reagents have been confirmed and recommended in the detection of SARS-CoV-2 Omicron variant by China NCCL.

Company profile

Bio-germ is a high-tech company dedicated to the development and application of molecular diagnostic reagents for infectious pathogens, especially multiple fluorescent PCR diagnostic reagents. Bio-germ provides total solutions from diagnostic reagents, diagnostic instruments, sequencing services and medical inspection services.

Bio-germ’s products are widely used in CDC, customs and ports, laboratories, medical institutions, disease control and public health, university scientific research etc.


For more detail information, please do not hesitate contact us. 

Shanghai Bio-germ Medical Technology Co., Ltd 

Tel:+86 21 67181107


ADD: Building No.3, Phoenix Creativity Valpley, No. 1588 Huhang Highway, Fengxian District, Shanghai